KR20240019215A - Cosmetic composition for skin moisturizing and skin soothing comprising an improved cell-permeable nuclear transport inhibitor - Google Patents

Abstract

The present invention relates to a composition comprising an improved cell-permeable nuclear import inhibitor (iCP-NI) peptide, and more specifically, to a composition having the effects of skin moisturizing, skin itching improvement, and erythema alleviation. It relates to a cosmetic composition or external skin preparation containing 1 as an active ingredient.

Description

Cosmetic composition for skin moisturizing and skin soothing comprising an improved cell-permeable nuclear transport inhibitor

Cross-reference to related applications

This application claims the benefit and priority of U.S. Provisional Patent Application Serial No. 63/232,766, filed August 13, 2021, which is incorporated herein by reference in its entirety.

The present invention relates to a composition comprising an improved cell-permeable nuclear import inhibitor (iCP-NI) peptide, and more specifically, to a composition having the effects of skin moisturizing, skin itching improvement, and erythema alleviation. It relates to a cosmetic composition or external skin preparation containing 1 as an active ingredient.

The skin is largely divided into three layers: epidermis, dermis, and subcutaneous fat tissue, and its function is to protect the human body from physical and chemical stimulation from the external environment. In particular, the skin transports about 65 to 70% of the moisture contained in the human body, that is, various physiologically active substances necessary for the human body, and plays a role in helping the skin maintain a soft and moist state. In addition, the epidermis is divided from the outside into the stratum corneum, stratum granulosum, stratum spinosum, and stratum basale. The cells of the stratum corneum act like bricks, and the intercellular lipids between keratinocytes act like mortar, forming a skin barrier. (J. Invest. Dermatol. 80(Suppl.), 44-49. 1983). The stratum corneum of the epidermis contains about 10 to 20% of moisture and is present in the outermost layer of the human body, suppressing moisture evaporation to the outside of the body and blocking excessive penetration of substances from the outside. The surface of these stratum corneum is covered with a thin natural protective film made of sebum from sebaceous glands and sweat from sweat glands, preventing evaporation of moisture. The cells that make up the stratum corneum of the skin contain a high concentration of Natural Moisturizing Factor (NMF), a water-soluble ingredient that not only acts to make the skin more flexible but also helps it maintain adequate moisture. For example, amino acids and The same substance is not only water-soluble, but also effectively binds moisture and prevents moisture from drying out of the skin (J. Invest. Dermatol. 54, 24-31, 1970).

However, various factors such as artificial temperature control due to changes in the environment or lifestyle patterns, skin stress due to various stresses and environmental pollution arising from social life, frequent face washing due to makeup habits, and natural skin aging due to age increase, etc. Due to this, the moisture in the stratum corneum decreases, causing the skin to dry out, the surface to become rough, the skin to lose its luster and appear dull, etc., so the need for skin moisturizers is increasing.

Meanwhile, as a way to maintain skin moisture, the most widely used method is to increase moisture retention in the stratum corneum using occlusive moisturizers that prevent moisture evaporation. However, these methods have Due to its physical properties, it has the disadvantage of being very sticky or feeling damp, and in addition, conventionally used skin moisturizers can cause skin problems, so there is a problem with skin safety. Therefore, there is a need to develop a skin moisturizer that is more stable and has an excellent moisturizing effect.

Under the above background, the present inventors introduced aMTD (advanced macromolecule transduction domain) based on TSDT (therapeutic molecule systemic delivery technology) into a cell-permeable nuclear import inhibitor (CP-NI, cSN50.1 peptide) to develop a peptide with improved solubility and stability. An improved cell-permeable nuclear import inhibitor (iCP-NI) was manufactured, and the iCP-NI not only has excellent biocompatibility, but also has a skin moisturizing effect, itching improvement, and erythema alleviation effect. After confirmation, the present invention was completed.

The present invention provides a skin moisturizing and skin soothing cosmetic composition containing an improved cell-permeable nuclear import inhibitor (iCP-NI) peptide consisting of the amino acid sequence shown in SEQ ID NO: 1 as an active ingredient. The purpose is to

In the cosmetic composition according to the present invention, the skin soothing may include reducing skin itching, improving skin erythema sensitivity, and skin redness.

In the cosmetic composition according to the present invention, the iCP-NI peptide may be contained at a concentration of 0.001 to 20 mM in the cosmetic composition.

In the cosmetic composition according to the present invention, the formulation of the cosmetic composition includes lotion (skin lotion), skin softener, skin toner, astringent, lotion, milk lotion, moisture lotion, nutritional lotion, massage cream, nutritional cream, eye cream, and moisture. One or more may be selected from the group consisting of cream, hand cream, foundation, essence, nutritional essence, pack, soap, cleansing foam, cleansing lotion, cleansing cream, body lotion, and body cleanser.

The present invention also provides a skin external agent for moisturizing and soothing skin containing an improved cell-permeable nuclear import inhibitor (iCP-NI) peptide consisting of the amino acid sequence shown in SEQ ID NO: 1 as an active ingredient. The purpose is to provide

In the skin external preparation according to the present invention, the formulation of the external preparation may be one or more selected from the group consisting of creams, gels, patches, sprays, ointments, warning agents, lotions, liniment agents, pasta agents, and cataplasma agents. there is.

The present invention also provides a skin moisturizing and skin soothing method comprising applying to a subject an improved cell-permeable nuclear import inhibitor (iCP-NI) peptide consisting of the amino acid sequence shown in SEQ ID NO: 1. The purpose is to provide.

The iCP-NI peptide according to the present invention not only has excellent biocompatibility, but also has a skin moisturizing effect and relieves itching caused by skin dryness, and has excellent skin care effects such as alleviating skin erythema, so it is effective as a cosmetic composition or external skin agent. It is expected that it can be used effectively.

Meanwhile, the scope of the present invention is not limited by the effects described above.

Figure 1 shows the biocompatibility of the iCP-NI peptide according to the present invention.
Figure 2 shows the erythema improvement effect of a cosmetic composition containing iCP-NI according to the present invention.
Figure 3 shows the effect of improving skin redness of a cosmetic composition containing iCP-NI according to the present invention.

Best mode for carrying out the invention

Hereinafter, a cosmetic composition containing an improved cell-permeable nuclear import inhibitor (iCP-NI) peptide according to a specific embodiment of the present invention will be described in detail. However, this is only an illustrative example, the scope of the present invention is not limited thereto, and it is obvious to those skilled in the art that various modifications to the embodiments are possible within the scope of the present invention.

As used herein, the term “include” or “comprise” means including a specific component (or element) without specific limitation, unless otherwise stated throughout the specification, and other components It cannot be interpreted as excluding the addition of (or elements).

As used herein, the term “amino acid” in its broadest sense includes naturally occurring L α-amino acids or residues thereof as well as D-amino acids and chemically modified amino acids. For example, amino acids may include mimetics and analogs of the amino acids described above. In the present disclosure, mimetics and analogs may include functional equivalents.

The term “skin” used herein refers to the tissue that covers the body surface of an animal, and is the broadest concept that includes not only the tissue that covers the body surface of the face or body, but also the scalp and hair.

As used herein, the term “skin itching” refers to an unpleasant sensation that causes a desire to scratch or rub the skin, and examples include itching caused by dry skin; Itching caused by hives; Itching caused by insect bites; Itching caused by heat rash, acne, ulcers, frostbite, contact dermatitis, seborrheic dermatitis, or psoriasis; Itching due to various skin diseases; Including scalp itching, etc. However, it goes without saying that the present invention does not exclude various causes of skin itching other than the skin itching listed above. The present invention includes all itch known in the art, such as itch of dermatological etiology, itch of systemic etiology, itch of neuropathic etiology and itch of psychogenic etiology.

The term “skin moisturizing” used in this specification refers to preventing evaporation of moisture from the skin to the outside of the body and blocking excessive penetration of external substances, thereby maintaining moisture in the stratum corneum of the skin and preventing the skin from drying out or the surface from becoming rough. , which means keeping the skin soft and moist.

The term “skin soothing” used herein means alleviating and soothing erythema or irritated skin areas.

The term “skin erythema” refers to a phenomenon in which the skin turns red due to external/internal stimulation, abnormal expansion of blood vessels, or erythema that develops due to blood pooling in skin tissue, etc., causing the skin to turn completely or partially red.

As used herein, the term “improvement” or “treatment” means (a) inhibiting the development of, (b) alleviating, and (c) eliminating a dermatitis disease in an individual.

As used herein, the term “prevention” refers to suppressing the occurrence of a disease or disease in an individual who has not been diagnosed as having the disease or disease but is prone to such disease or disease.

The term “application” used herein refers to any method of contacting the composition according to the present invention to the skin of an individual by any appropriate method, and the purpose is to allow the composition to be absorbed into the skin.

According to the first implementation example,

The present invention provides a cosmetic composition for moisturizing and soothing skin containing an improved cell-permeable nuclear import inhibitor (iCP-NI) peptide consisting of the amino acid of SEQ ID NO: 1 as an active ingredient.

The iCP-NI peptide according to the present invention is preferably contained in a cosmetic composition at a concentration of 0.01 to 10000 ppm, and more preferably contained at a concentration of 0.01 to 1000 ppm, but is not limited thereto. If the concentration of the peptide is less than 0.01 ppm, it is difficult to obtain the desired skin moisturizing and skin soothing effects, and if it exceeds 10000 ppm, there is no clear increase in effect as the content increases, resulting in low production economics.

The iCP-NI peptide according to the present invention can be produced by general chemical synthesis, for example, solid-phase peptide synthesis, and can be produced by a microorganism transformed with a recombinant vector containing a nucleic acid encoding the peptide. The peptide may be expressed by culturing and then purified and manufactured by a conventional method, but the peptide is not limited to this.

In addition to the above-mentioned peptide, the cosmetic composition according to the present invention may further contain other ingredients that can preferably have a synergistic effect on the effect of the above-mentioned peptide within a range that does not impair the effect aimed at by the present invention. For example, the cosmetic composition of the present invention contains conventional auxiliaries such as antioxidants, stabilizers, solubilizers, vitamins, pigments and fragrances, or carriers, as well as any other substances known to have skin moisturizing and skin soothing effects. It can be included.

The cosmetic composition according to the present invention is not particularly limited in its formulation and can be prepared in any formulation commonly manufactured in the art, for example, solution, suspension, emulsion, paste, gel, cream, It can be formulated as lotion, powder, soap, surfactant-containing cleansing, oil, powder foundation, emulsion foundation, wax foundation and spray. On the other hand, scalp treatments, soaps, hair tonics, shampoos, rinses, hair packs, hair gels, lotions, conditioners, hair oils, mousses, creams, solids, solutions, emulsions, dispersants, micelles, liposomes, ointments, It may also be manufactured in the form of lotion, essence, patch, or spray.

When the formulation of the cosmetic composition is paste, cream or gel, animal oil, vegetable oil, wax, paraffin, starch, tracant, cellulose derivative, polyethylene glycol, silicone, bentonite, silica, talc or zinc oxide are used as carrier ingredients. In the case of powder or spray, lactose, talc, silica, aluminum hydroxide, calcium silicate, or polyamide powder may be used as carrier ingredients, and especially in the case of spray, chlorofluorohydrocarbon, propane/ It may contain a propellant such as butane or dimethyl ether.

When the formulation of the cosmetic composition is a solution or emulsion, a solvent, solubilizing agent, or emulsifying agent may be used as a carrier component, for example, water, ethanol, isopropanol, ethyl carbonate, ethyl acetate, benzyl alcohol, and benzyl benzoate. , propylene glycol, 1,3-butyl glycol oil, glycerol fatty esters, polyethylene glycol, or fatty acid esters of sorbitan.

When the formulation of the cosmetic composition is a suspension, the carrier ingredients include water, a liquid diluent such as ethanol or propylene glycol, a suspending agent such as ethoxylated isostearyl alcohol, polyoxyethylene sorbitol ester, and polyoxyethylene sorbitan ester, and miso. Crystalline cellulose, aluminum metahydroxide, bentonite, agar, or tracant can be used, and in the case of cleansing containing surfactants, aliphatic alcohol sulfate, aliphatic alcohol ether sulfate, sulfosuccinic acid monoester, and isethionate are used as carrier ingredients. , imidazolinium derivatives, methyl taurate, sarcosinate, fatty acid amide ether sulfate, alkylamidobetaine, fatty alcohol, fatty acid glyceride, fatty acid diethanolamide, vegetable oil, lanolin derivative or ethoxylated glycerol fatty acid ester, etc. It can be used.

According to a specific embodiment of the present invention, the iCP-NI peptide of the present invention has excellent biocompatibility and has the effect of reducing skin itchiness, increasing skin moisture and dielectric constant, reducing transepidermal water loss, reducing skin erythema caused by ultraviolet rays, and improving skin redness. have Therefore, the iCP-NI peptide of the present invention can be usefully used as an active ingredient in cosmetic compositions for skin moisturization and skin soothing.

According to the second implementation,

The present invention provides a pharmaceutical composition for skin moisturizing and skin soothing comprising an improved cell-permeable nuclear import inhibitor (iCP-NI) peptide consisting of the amino acid of SEQ ID NO: 1 as an active ingredient.

The pharmaceutical composition according to the present invention includes dermal, oral, intravenous, intramuscular, intraarterial, transdermal, subcutaneous, intraperitoneal, intranasal, enteral, topical, sublingual or rectal administration, and oral or parenteral administration is preferred. However, it is not limited to this. The parenteral administration includes subcutaneous, intradermal, intravenous, intramuscular, and intralesional injection or infusion techniques.

The pharmaceutical composition according to the present invention may contain one or more active ingredients that exhibit the same or similar functions in addition to the iCP-NI peptide according to the present invention. The composition can be formulated and used in the form of oral dosage forms such as powders, granules, tablets, capsules, suspensions, emulsions, syrups, external preparations, suppositories, and sterile injection solutions according to conventional methods.

Solid preparations for oral administration of the pharmaceutical composition include powders, granules, tablets, capsules, soft capsules, pills, etc. Liquid preparations for oral use include suspensions, oral solutions, emulsions, syrups, etc. In addition to the commonly used simple diluents such as water and liquid paraffin, various excipients such as wetting agents, sweeteners, fragrances, and preservatives may be included. . Preparations for parenteral administration include external preparations such as powders, granules, tablets, capsules, sterilized aqueous solutions, solutions, non-aqueous solvents, suspensions, emulsions, syrups, suppositories, aerosols, etc. and sterilized injection preparations according to conventional methods. It can be formulated and used in the form of a cream, gel, patch, spray, ointment, warning agent, lotion, liniment agent, pasta agent, or cataplasma agent. It can be prepared and used as a pharmaceutical composition for external use on the skin. , but is not limited to this. Non-aqueous solvents and suspensions may include propylene glycol, polyethylene glycol, vegetable oil such as olive oil, and injectable ester such as ethyl oleate. As a base for suppositories, witepsol, macrogol, tween 61, cacao, laurin, glycerogeratin, etc. can be used.

The pharmaceutical composition according to the present invention may further contain preservatives, stabilizers, hydrating agents or emulsification accelerators, auxiliaries such as salts and/or buffering agents for adjusting osmotic pressure, and other therapeutically useful substances, and may be prepared by conventional methods. It can be formulated according to mixing, granulating or coating methods.

The pharmaceutical composition according to the present invention may vary depending on various factors, including the subject's age, weight, general health, gender, administration time, administration route, excretion rate, drug combination, and severity of a specific disease.

When the pharmaceutical composition according to the present invention is formulated in a unit dose form containing the iCP-NI peptide as an active ingredient, the iCP-NI peptide as an active ingredient is administered in a unit dose of about 0.01 to 1,500 mg. It is preferable to contain it, and the dosage required for adult treatment is usually in the range of about 1 to 500 mg per day depending on the frequency and intensity of administration, but is not limited thereto. When administered intramuscularly or intravenously to adults, a single dose of approximately 5 to 300 mg per day will usually be sufficient, although higher daily doses may be desirable for some patients. The composition of the present invention can be used alone or in combination with surgery, radiation therapy, hormone therapy, chemotherapy, and methods using biological response modifiers.

According to the third implementation example,

The present invention includes the step of treating or administering a cosmetically or pharmaceutically effective amount of an improved cell-permeable nuclear import inhibitor (iCP-NI) peptide consisting of the amino acid of SEQ ID NO: 1 to an individual. Provides skin moisturizing and skin soothing methods.

In the method according to the present invention, the cosmetically or pharmaceutically effective amount is 0.0001 to 100 mg/kg, preferably 0.001 to 10 mg/kg, but is not limited thereto. Treatment or dosage can be adjusted depending on the specific patient's weight, age, gender, health condition, diet, administration period, administration method, clearance rate, disease severity, etc. Treatment or administration may be administered once a day or may be divided into several times.

In the method according to the present invention, the subject is a vertebrate, preferably a mammal, more preferably a human or laboratory animal such as a rat, rabbit, guinea pig, hamster, dog, or cat, and most preferably a human. It may be, but is not limited to this.

In the method according to the present invention, the treatment or administration method can be applied, orally or parenterally, and when administered parenterally, intraperitoneal injection, intrarectal injection, subcutaneous injection, intravenous injection, intramuscular injection, intrauterine dura. It may be administered by injection, intracerebrovascular injection, or intrathoracic injection.

Forms for practicing the invention

Hereinafter, the present invention will be described in more detail through examples and experimental examples. However, the following examples and experimental examples are for illustrating the present invention, and the content of the present invention is not limited to the following examples and experimental examples.

<Manufacturing example>

1. Preparation of improved cell-permeable nuclear transport inhibitor (iCP-NI)

The iCP-NI peptide consisting of the amino acid sequence of SEQ ID NO: 1 according to the present invention uses an advanced macromolecule transduction domain (aMTD) consisting of the amino acid of SEQ ID NO: 2 and the NF-κ nuclear site sequence (NLS) consisting of the amino acid of SEQ ID NO: 3. It was prepared (Table 1).

designation order SEQ No. iCP-NI IAAVLAAPALVPCVQRKRQKLMPC SEQ ID NO: 1 aMTD IAAVLAAPALVP SEQ ID NO: 2 NLS CVQRKRQKLMPC SEQ ID NO: 3

2. In-vitro efficacy evaluation of biocompatibility of iCP-NI peptide

NHDF cells were inoculated into a ²⁴ -well plate at a concentration of 2.0 ) was exchanged for serum-free FBM containing FBM and cultured for 24 hours. After incubation, 50 μl of EZ-Cytox was added per well and cultured for another hour. The cultured medium was transferred to a 96-well plate and the absorbance was measured at 450 nm using a VERSA max microplate reader (Molecular devices, LCC., USA). The average absorbance value for each sample group was obtained, and cell survival rate was investigated by comparing it with the absorbance value of the control group. As a result, it was confirmed that the iCP-NI peptide according to the present invention had no cytotoxicity compared to the control group in the concentration range of 1 to 50 μM (Figure 1).

3. Preparation of cosmetics containing iCP-NI peptide

A lotion containing the iCP-NI peptide of the present invention as an active ingredient was prepared as shown in Table 2 below (content: parts by weight).

division Ingredient name Formulation example Comparative example Awards WATER To. 100 To. 100 GLYCERIN 5 5 1,3-BUTYLENE GLYCOL 8 8 1,2-Hexanediol 2 2 EDTA-2Na 0.02 0.02 AMMONIUM ACRYLOYLDIMETHYLTAURATE/VP COPOLYMER 0.5 0.5 paid CETEARYL ALCOHOL 2.0 2.0 PEG-100 STEARATE 1.5 1.5 GLYCERYL STEARATE 0.7 0.7 BEESWAX One One CETYLETHYLHEXANOATE 5 5 SQUALANE 3 3 C14-22 ALCOHOL 2.0 2.0 POLYSORBATE 20 0.5 0.5 SOLBITAN ISOSTEARATE 1.2 1.2 C12-20 ALKYLGLUCOSIDE 0.5 0.5 CYCLOMETHICONE 2 2 DIMETHICONE One One DIMETHICONOL 0.5 0.5 iCP-NI Award WATER One - iCP-NI 0.01 - additive FRAGRANCE Appropriate amount Appropriate amount

<Experimental example>

1. Evaluation of the itching alleviation efficacy of iCP-NI according to the present invention

A human application test was conducted to verify the functionality of iCP-NI according to the present invention. After washing the face and cheek area, the patient waited at least 30 minutes under constant temperature and humidity (22 ± 2°C, 50 ± 5%) conditions to sufficiently stabilize the skin before participating in the test. The itching score (Score), skin moisture content (A.U.) of the cheek area, and average dielectric constant (ε transepidermal water loss (g/m2h)) were measured before and after using the test product to evaluate the efficacy of relieving itching caused by dryness.

(1) Itch score

Before using the test product, after using it for 2 weeks, and after using it for 4 weeks, the test subjects were asked to self-evaluate the itching classification on a 10-point scale according to Table 3 below, and the average of the scores was calculated to evaluate the degree of improvement in itching.

score Degree of itching 0 points no itchiness 1 point or more but less than 3 points Mild pruritus 3 or more points but less than 7 points Moderate pruritus 7 or more points but less than 9 points Severe pruritus 10 points very severe pruritus

As a result, it was confirmed that the cosmetic composition containing iCP-NI according to the present invention significantly reduced the itching scores after 2 weeks of use and 4 weeks of use compared to before use.

division Mean ± standard deviation improvement rate p-value test site Before exam 4.95±1.76 - <0.001 2 weeks after exam 2.73±1.70 44.95% 4 weeks after exam 1.59±0.73 67.89%

(2) Skin moisture content (A.U.)

The skin moisture content was evaluated by measuring the capacitance of the stratum corneum within 10 ㎛ from the skin surface using the Corneometer CM825 Probe (Courage+Khazaka GmbH, Germany). As a result, it was confirmed that the cosmetic composition containing iCP-NI according to the present invention significantly increased the amount of skin moisture after 2 weeks of use and after 4 weeks of use compared to before use.

division Mean ± standard deviation improvement rate p-value test site Before exam 27.00±2.25 - <0.001 2 weeks after exam 31.42±3.59 16.37% 4 weeks after exam 34.40±3.46 27.42%

(3) Average permittivity

Epsilon E100 (Biox Systems Ltd., England) used a CMOS fingerprint recognition sensor with a special resolution of 50㎛ to calculate the average dielectric constant (ε value) of the amount of moisture on the skin surface in contact with the sensor in an area of 12.8mm*15mm. As a result, It was confirmed that the cosmetic composition containing iCP-NI according to the present invention significantly increased the skin permittivity after 2 weeks of use and after 4 weeks of use compared to before use.

division Mean ± standard deviation improvement rate p-value test site Before exam 18.99±5.90 - <0.001 2 weeks after exam 22.28±5.90 17.31% 4 weeks after exam 24.88±5.76 31.01%

(4) Transepidermal water loss

Vapometer (Delfin Technologies Ltd., Finland) evaluated transepidermal water loss (TEWL), an indicator of water loss through the epidermis. As a result, it was confirmed that the cosmetic composition containing iCP-NI according to the present invention significantly reduced the skin dielectric constant after 2 weeks of use and after 4 weeks of use compared to before use.

division Mean ± standard deviation improvement rate p-value test site Before exam 18.96±5.05 - <0.001 2 weeks after exam 16.86±4.54 11.10% 4 weeks after exam 15.47±4.71 18.42%

2. Evaluation of skin soothing efficacy by ultraviolet ray stimulation of iCP-NI according to the present invention

Stimulation through ultraviolet rays was induced on human skin, and iCP-NI (0.01%) was applied to the erythema area formed as a result, and then compared with the non-application group 48 hours later. The a* value (redness) of the test area was measured using a spectrophotometer CM-26dG (Konica Minolta). As a result, it was confirmed that the cosmetic composition containing iCP-NI according to the present invention reduces the minimum erythema degree (MED) induced by ultraviolet rays after 48 hours (FIG. 2).

3. Evaluation of the skin redness improvement efficacy of iCP-NI according to the present invention

A human application test was conducted on 20 test subjects. After washing the cheek area of the face, the patient waited at least 30 minutes under constant temperature and humidity (22 ± 2°C, 50 ± 5%) conditions to sufficiently stabilize the skin before participating in the test. Before using the test product and after using it for 4 weeks, skin redness was evaluated on the cheek area using photography and image analysis program using VISIA-CR. As a result, it was confirmed that the cosmetic composition containing iCP-NI according to the present invention improved skin redness by about 42% after 4 weeks of use (FIG. 3).

The iCP-NI peptide of the present invention has excellent biocompatibility and has the effect of reducing skin itchiness, increasing skin moisture and dielectric constant, reducing transepidermal water loss, reducing skin erythema caused by ultraviolet rays, and improving skin redness. Therefore, the iCP-NI peptide of the present invention can be usefully used as an active ingredient in cosmetic compositions for skin moisturization and skin soothing.

Claims (7)

A cosmetic composition for skin moisturizing and skin soothing comprising an improved cell-permeable nuclear import inhibitor (iCP-NI) peptide consisting of the amino acid sequence shown in SEQ ID NO: 1 as an active ingredient. According to paragraph 1,
A cosmetic composition, wherein the skin soothing includes reducing skin itching, improving skin erythema sensitivity, and skin redness. According to paragraph 1,
A cosmetic composition, wherein the iCP-NI peptide is contained in a concentration of 0.01 to 10000 ppm in the cosmetic composition. According to paragraph 1,
The formulation of the cosmetic composition includes lotion (skin lotion), skin softener, skin toner, astringent, lotion, milk lotion, moisture lotion, nutritional lotion, massage cream, nutritional cream, eye cream, moisture cream, hand cream, foundation, essence, A cosmetic composition characterized by one or more selected from the group consisting of nutritional essence, pack, soap, cleansing foam, cleansing lotion, cleansing cream, body lotion and body cleanser. An external skin preparation for moisturizing and soothing skin containing an improved cell-permeable nuclear import inhibitor (iCP-NI) peptide consisting of the amino acid sequence shown in SEQ ID NO: 1 as an active ingredient. According to clause 5,
The formulation of the external preparation is one or more selected from the group consisting of creams, gels, patches, sprays, ointments, warning agents, lotions, liniment agents, pasta agents, and cataplasma agents. A skin moisturizing and skin soothing method comprising applying to a subject an improved cell-permeable nuclear import inhibitor (iCP-NI) peptide consisting of the amino acid sequence represented by SEQ ID NO: 1.

Images